Key facts
- This page summarizes Daphne Quimi's Form 4 filing for AMICUS THERAPEUTICS, INC. (FOLD).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 19 Jan 2023, 17:16.
Daphne Quimi - 17 Jan 2023 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- FOLD
- Reported as of
- 17 Jan 2023
- Net transaction value
- -$152,444
- SEC form
- 4
- Accepted by SEC
- 19 Jan 2023, 17:16:09 UTC
- Prior SEC filing
- 13 Jan 2023
- Next SEC filing
- 12 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christian Formica, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daphne Quimi filed Form 4 for AMICUS THERAPEUTICS, INC. (FOLD) on 19 Jan 2023.
Change
- Previous filing in this sequence was filed on 13 Jan 2023.
- Current net transaction value: -$152,444.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FOLD
transaction
Common Stock
Sale
- Transaction value
- $62,444
- Shares
- -5,000
- Change %
- -1.2%
- Price
- $12.49
- Shares after
- 405,455
- Date
- 17 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F2
FOLD
transaction
Common Stock
Sale
- Transaction value
- $89,999
- Shares
- -6,923
- Change %
- -1.7%
- Price
- $13.00
- Shares after
- 398,532
- Date
- 18 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F2
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.34 to $12.70. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.